🇺🇸 FDA
Pipeline program

Casimersen

4045-302

Phase 3 small_molecule terminated

Quick answer

Casimersen for Duchenne Muscular Dystrophy is a Phase 3 program (small_molecule) at Sarepta Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Sarepta Therapeutics
Indication
Duchenne Muscular Dystrophy
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials